Beyond Air, Inc. (XAIR) stock declined over -3.46%, trading at $3.07 on NASDAQ, down from the previous close of $3.18. The stock opened at $3.16, fluctuating between $3.06 and $3.19 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | 3.16 | 3.19 | 3.06 | 3.07 | 43.62K |
| Sep 09, 2026 | 3.40 | 3.43 | 3.18 | 3.18 | 54.72K |
| Sep 08, 2026 | 3.51 | 3.58 | 3.32 | 3.38 | 83.88K |
| Sep 04, 2026 | 3.55 | 3.64 | 3.50 | 3.53 | 47.35K |
| Sep 03, 2026 | 3.60 | 3.69 | 3.52 | 3.59 | 0 |
| Sep 02, 2026 | 3.61 | 3.95 | 3.61 | 3.62 | 142.08K |
| Sep 01, 2026 | 3.78 | 3.94 | 3.60 | 3.66 | 265.51K |
| Aug 31, 2026 | 4.52 | 4.52 | 3.85 | 3.97 | 8.73M |
| Aug 28, 2026 | 4.39 | 4.73 | 4.25 | 4.48 | 311.68K |
| Aug 27, 2026 | 4.94 | 5.70 | 4.60 | 5.70 | 1.09M |
| Aug 26, 2026 | 4.96 | 4.97 | 4.70 | 4.97 | 14.56K |
| Aug 25, 2026 | 4.68 | 5.07 | 4.37 | 4.98 | 289.63K |
| Aug 24, 2026 | 5.12 | 5.49 | 4.85 | 4.91 | 21.95K |
| Aug 21, 2026 | 5.30 | 5.31 | 4.88 | 5.04 | 23.56K |
| Aug 20, 2026 | 5.12 | 5.55 | 5.01 | 5.16 | 30.85K |
| Aug 19, 2026 | 5.95 | 5.95 | 5.09 | 5.21 | 69.9K |
| Aug 18, 2026 | 5.70 | 5.85 | 5.60 | 5.73 | 17.86K |
| Aug 17, 2026 | 6.25 | 6.25 | 5.71 | 5.71 | 22.08K |
| Aug 14, 2026 | 6.98 | 7.00 | 6.22 | 6.32 | 15.3K |
| Aug 13, 2026 | 6.65 | 7.23 | 5.89 | 6.92 | 0 |
Beyond Air, Inc. functions as a specialized entity involved in both the development of medical devices and biopharmaceutical solutions. A central part of its operations is the LungFit platform, an innovative system that generates and delivers nitric oxide. Within this platform, LungFit PH is currently available, used to address persistent pulmonary hypertension in infants. Furthermore, the company is advancing LungFit PRO, a product intended for various viral lung ailments like community-acquired viral pneumonia (including COVID-19) and bronchiolitis in hospital settings. It is also creating LungFit GO, which aims to treat nontuberculous mycobacteria infections. The organization adopted its current name, Beyond Air, Inc., in June 2019, having previously been known as AIT Therapeutics, Inc. Its headquarters are situated in Garden City, New York.
| Employees | 54 |
| Beta | 0.15 |
| Sales or Revenue | $7.68M |
| 5Y Sales Change% | -0.952% |
| Fiscal Year Ends | March |
| Sector | Healthcare |
| Industry | Medical - Devices |
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep